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Abstract 
Spray drying plays a crucial role in the processing of pharmaceutical products 
such as pills, capsules, and tablets as it is used to convert drug containing 
liquids into dried powdered forms. Nano spray drying is in particular used to 
improve drug formulation by encapsulating active ingredients in polymeric 
wall materials for protection and delivering the drugs to the right place and 
time in the body. The nano spray dryer developed in the recent years extends 
the spectrum of produced powder particles to the submicron- and nanoscale 
with very narrow size distributions and sample quantities in the milligram 
scale at high product yields. This enables the economical use of expensive 
active pharmaceutical ingredients and pure drugs. The present paper explains 
the concept of nano spray drying and discusses the influence of the main 
process parameters on the final powder properties like particle size, 
morphology, encapsulation efficiency, and drug loading. Application results 
of nano spray drying for the formulation and encapsulation of different drugs 
are reviewed. 
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1. Introduction 
Spray drying is a simple, fast, and scalable drying technology that is well established in the 
pharmaceutical industry. Many pharmaceutical products such as pills, capsules, and tablets 
are processed in dried powdered form. In the course of the rapid progress of nanocapsulation 
techniques, nano spray drying technology has developed to improve the formulation and 
administration of drugs with solid colloidal particles in the submicron size range. It enables 
the encapsulation of active ingredients in polymeric wall materials providing enhanced 
environmental protection (e.g. against oxidation, light, and temperature), stability, handling, 
storage, and controlled drug release properties. The nanonization and structual change 
improves the particle solubility and redispersibility of the final drug product in aqueous 
solutions. This study explains the concept of nano spray drying, the influence of the main 
process parameters on the powder properties (e.g. particle size, morphology, encapsulation 
efficiency, drug loading), and discusses different pharmaceutical applications. More detailed 
information on the formation of nanocapsules by nano spray drying can be found in several 
review studies [1–12], in particular in a recently published book chapter by Arpagaus et al. 
[1]. 
2. Process Parameters of a Nano Spray Dryer 
Figure 1 shows the functional principle of a nano spray dryer and the adjustable process 
parameters and formulation variables. The droplet generation is based on vibrating mesh 
technology ejecting precisely sized droplets into the drying chamber.  
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With a 4.0 µm spray mesh approximately 3 to 8 µm water droplets are produced [1,8]. The 
dried particles are captured in an electrostatic particle collector providing high particle 
collection efficiency. The cooling effect of the evaporating solvent keeps the droplet 
temperature low, so that heat sensitive products can be dried with negligible degradation. 
Table 1 povides an overview of the main process parameters and their influence on the final 
powder product. The thickness of each arrow illustrates the strength of the relationship. The 
key parameters controlling the final particle size are the spray mesh size and the solid 
concentration. The submicron size is typically reached when a 4.0 µm spray mesh and diluted 
solutions of 0.1 to 1% (w/v) are used.  
Table 1 Influence of the main process parameters in nano spray drying (/ strong, / weak 














Drying gas flow rate   ̶ ̶ ̶  ̶ ̶ 
Drying gas humidity   ̶ ̶ ̶   ̶ 
Inlet temperature   ̶  ̶    
Spray mesh size      ̶ ̶  
Spray rate intensity       ̶  
Circulation pump rate  ̶    ̶ ̶  
Solid concentration   ̶     ̶ 
Surfactant / stabilizer  ̶    ̶   
Solvent instead of water       ̶ 
 
Depending on the application, an optimized set of process parameters can be found, e.g. by 
design of experiment studies [1]. Organic solvents like dichloromethane, acetone, ethanol, 
methanol, acetonitrile, ethylacetate, and mixtures thereof with water are typically used in 
nano spray drying of pharmaceuticals. The selection is based on the drug solubilization and 
the encapsulating wall materials, as well as on the required drying temperatures. For 
acqueous applications, the outlet temperatures range between 28 and 59 °C [2]. The optimal 
drying temperatures of for example poly(lactic-co-glycolic acid) (PLGA) dissolved in 
dichloromethane lies in a range of 29 to 32 °C [12].  
Numerous excipients, dispering agents, binders and stabilizers are applied in drug 
formulation studies, including water-soluble saccharides (e.g. arabic gum, alginate, chitosan, 
cyclodextrin, cellulose derivatives, modified starch, maltodextrin, pectin, mannitol, lactose 
trehalose), proteins (i.e. gelatin, serum albumin, whey protein, sodium caseinate, silk fibroin, 
leucine), water-soluble synthetic polymers (e.g. poly(vinyl alcohol), poly(ethylene glycol) or 
poly(acrylic acid) (Carbopol)), hydrophobic synthetic polymers (e.g. PLGA, poly(ε-
caprolactone), poly(vinyl pyrrolidone) (Kollidon), Eudragit), and fats (e.g. stearic acid and 
glyceryl behenate (Compritol)).  
613
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The morphology of particles prepared by nano spray drying depends on the drying conditions 
and the feed properties. Dense, hollow, porous, composites, and encapsulated structures (i.e. 
single-core, multi-core, irregular, or multi-walled) with spherical, wrinkled, shriveled, or 
even doughnut-like shapes can be obtained [1]. Figure 2 illustrates some examples of nano 
spray dried particles including salbutamol, albuterol in mannitol, cyclosporine in PLGA, 
trehalose, β-galactosidase in trehalose, and bovine serum albumin.  
 
Figure 2 Examples of nano spray dried particles: A: Salbutamol sulfate (1% solid concentration, 
nano spray dried at 100 °C) [13]; B: Albuterol sulfate in mannitol, L-leucine and poloxamer 188 
(30:48:20:2 mixing ratio, 0.5% in water-ethanol solution (80:20), 70 °C) [14]; C: Cyclosporin in 
PLGA (50:50, 15 kDa, dissolved in DCM, 29°C) [12]; D: Trehalose with addition of 0.005% 
polysorbate 20 (0.1%, 120 °C) [8]; E: β-galactosidase in trehalose (1:2 mixing ratio, 5%, 80°C) 
[11]; F: Bovine serum albumin with 0.05% Tween 80 (0.5%, 120 °C) [6]. 
 
In general, slow drying leads to more compact particles, while fast and high temperature 
drying favours the formation of hollow particles with thin shells. Surfactants balance the 
surface-to-viscous forces inside of the drying droplet and enable the formation of a smooth 
spherical surface. Composite particles prepared from suspensions and nano spray drying 
provide a high specific surface area. Most nano spray dried drugs tend to be amorphous due 
to the too short drying time to form crystalline structures. To prevent recrystallization, the 
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3. Applications of Nano Spray Dried Pharmaceuticals 
The number of publications on nano spray dried pharmaceuticals has risen sharply after the 
market launch of the Nano Spray Dryer B-90 in 2009 [1]. The formulations contain drugs 
and excipients for the treatment of various diseases, including  
• asthma (e.g. salbutamol, terbutaline, or fluticasone),  
• inflammation (e.g. dexamethasone and azithromycin, or pain and fever reducer 
indomethacin and nimesulide),  
• cystic fibrosis (e.g. antibacterial dexketoprofen in Kollidon and Eudragit 
nanoparticles, or azithromycin in leucine),  
• diabetes (e.g. sitagliptin, vildagliptin, and metformin in mucoadhesive Carbopol and 
gelatin),  
• pulmonary arterial hypertension (e.g. resveratrol in poly(caprolactone), or sildenafil 
in PLGA),  
• tuberculosis (e.g. capreomycin or pyrazinamide in L-leucine, or ethambutol mixed 
with chitosan carrier particles),  
• Alzheimer's and Parkinson's diseases (e.g. nanocrystals of calpain inhibitor 
steroids),  
• breast cancer (e.g. simvastatin loaded PLGA particles), or lung cancer (e.g. 
methotrexate, carboplatin in gelatine, or paclitaxel),  
• bacterial infections (e.g. amoxicillin, ciprofloxacin, gatifloxacin, clarithromycin, or 
levofloxacin),   
• fungal infections (e.g. antifungal griseovulfin) 
• ophthalmic disorders (e.g. calpain inhibitor nanocrystals or dirithromycin 
incorporated in Kollidon), 
• high blood pressure (e.g. nimodipine in PLGA or pure nicergoline nanoparticles), 
• congestive heart failure and edema (e.g. diuretic furosemide). 
The drug-loaded nano spray dried particles are administered in various ways underlining the 
versatility of the applications, such as mainly pulmonary (e.g. optimized respirable particles 
of 1 to 5 µm size) and oral, but also intravenous (e.g. simvastatin in PLGA as cancer 
chemotherapeutics, antipsychotic clozapine and risperidone in PLGA, or small interfering 
RNAs loaded in human serum albumin particles to treat genetic disorders), topically as 
creams to the skin (e.g. anti-inflammatory dexamethasone, antibacterial gentamicin in 
615
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gelatin-pectine, amoxicillin loaded chitosan, antifungal econazole in cyclodextrin, soy 
isoflavones for skin cancer treatment or as anti-ageing agent), or as nanoparticulate powder 
(e.g. as a wound dressing during surgery), ophthalmic (e.g. anti-inflammatory steroids in eye 
drop solutions, or dirithromycin to treat ocular bacterial infections), intraperitoneal (e.g. 
encapsulated paclitaxel as cytostatic in anticancer therapy), intravesical (e.g. as drug delivery 
system to treat local bladder diseases), and even cerebral (e.g. with nimodipine in PLGA 
regulating the dilatation of blood vessels). 
Typical experimental process parameters for nano spray drying are listed in Table 2 and can 
be used as first guess values for applying identical or similar substances. The main organic 
solvents used to dissolve poorly water soluble drugs are ethanol, acetone, and DCM. With 
highly diluted solutions containing 0.1 to 1% (w/v) solids concentrations, finest solid 
particles down to 100 nm can be obtained by nano spray drying. 



























60 to 120 
50 to 110 
40 to 70 
30 to 50 
30 to 60 
30 to 50 
25 to 40 





100 to 140 
100 to 120 
90 to 120 
80 to 120 




5 to 25 
20 to 65 
30 to 160 
 
Pure drug particles in the nanosize dimensions and the amorphous state offer higher 
absorption rates and bioavailability, and encourage future developments in this research area. 
Nanocapsules, with their reduced size and large specific surface area, provide pronounced 
improvement in controlled drug release and bioavailabilty. This enables the generation of 
target drug delivery systems. Under optimized conditions uniquely high product yields of 
about 76 to 96% can be achieved to process small sample amounts of substances in the range 
of 10 mg to 2.5 g.  
Variations in the yield may occur due to particle depositions around the spray cap and the 
chamber walls, nozzle blockage, or due to losses during the manual collection of the powder 
with a rubber spatula.  
However, the ability to process small sample amounts makes a nano spray dryer very suitable 
for testing valuable biological materials such as for example monoclonal antibodies, 
recombinant proteins, or siRNA-based therapeutics. Moreover, nano spray drying enables 
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4. Conclusions 
Nano spray drying has been successfully applied for a wide range of pharmaceutical 
applications, such as increasing the bioavailability of poorly soluble drugs by nanoisation 
and structural modification, as well as the encapsulation of nanoparticles, nanoemulsions and 
nanosuspensions in biocompatible polymeric wall materials for sustained drug release. 
Encapsulation efficiencies of over 95% are achieved by adjustable drug loadings. Smallest 
sample amounts ranging from 10 mg to 2.5 g with uniquely high yields of over 95% can be 
processed, which enables the economical use of valuable active pharmaceutical ingredients. 
Compared to conventional spray drying processes, nano spray drying relies on vibrating mesh 
technology to produce an ultrafine spray. A highly efficient electrostatic powder collector to 
extend the size spectrum of separable particles to the nanoscale.  
The most important adjustable process parameters are the drying gas temperature, the drying 
gas flow rate, the spray mesh size, the solvent type, the solids concentration in the feed, and 
the selection of the corresponding exipients, stabilizers and surfactants. Depending on the 
application, an optimized set of parameters can be found. Submicron spray dried particles 
can be formed down to a size of only 100 nm with diluted solutions of 0.1 to 1% (w/v) solids 
concentration. Different particle morphologies can be created, including dense, hollow and 
porous particles with spherical, wrinkled, or donut shapes.  
The drying process is gentle and contributes to maintaining the stability and activity of heat-
sensitive materials, such as peptides, proteins, hormones and amino acids. The prepared drug 
loaded particles are administered in various ways, including pulmonary, oral, intravenous, 
topically, ophthalmic, intraperitoneal, intravesical, or even cerebral, which underlines the 
versatility of the nano spray drying technology.  
To further explore the potentials of nano spray drying future research should focus on the 
further commercialization of this technology to an industrial scale. There is an increasing 
need for scale-up.  
The main application trends are in the areas of pulmonary drug delivery, nanotherapeutics, 
the encapsulation of nanoemulsions with poorly water-soluble active ingredients and the 
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